A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease

scientific article (publication date: 15 January 2004)

A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1056/NEJMOA032441
P3181OpenCitations bibliographic resource ID2114875
P698PubMed publication ID14724301

P50authorStephen G. EllisQ62496584
Jeffrey PopmaQ87844791
Gregg W StoneQ90754539
James B HermillerQ114304401
Mark A TurcoQ114304436
Ronald P CaputoQ114406348
James Tift MannQ114445140
P2093author name stringDavid A Cox
Mary E Russell
Charles O'Shaughnessy
Joel Greenberg
Patrick Bergin
P433issue3
P407language of work or nameEnglishQ1860
P921main subjectcoronary artery diseaseQ844935
P304page(s)221-31
P577publication date2004-01-15
P1433published inThe New England Journal of MedicineQ582728
P1476titleA polymer-based, paclitaxel-eluting stent in patients with coronary artery disease
P478volume350

Reverse relations

cites work (P2860)
Q45005007"Active" endoprosthesis with in situ release of an antimitotic or cytostatic drug: a revolution that cannot do without thought
Q30356028"Do least harm" philosophy may suffice for percutaneous coronary intervention in octogenarians.
Q5142951532P brachytherapy in the treatment of complex Cypher in-stent restenosis.
Q5705825240 Years of Percutaneous Coronary Intervention: History and Future Directions
Q587998039-year clinical follow-up of patients with ST-segment elevation myocardial infarction with Genous or TAXUS Liberté stents
Q40119069A HUVEC line with a stable expression of the VEGF121 gene to achieve complete endothelialization of blood conduits
Q34761876A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial
Q36973815A cardiologist view of vascular disease in diabetes
Q45125928A comparative analysis of major clinical outcomes using drug-eluting stents versus bare metal stents in diabetic versus nondiabetic patients.
Q37385456A comparison of bare-metal and drug-eluting stents for off-label indications
Q47161708A comparison of the main outcomes from BP-BES and DP-DES at five years of follow-up: A systematic review and meta-analysis
Q45019905A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents
Q38563035A journey from CABG to drug-eluting balloon
Q92723448A novel CD147 inhibitor, SP-8356, reduces neointimal hyperplasia and arterial stiffness in a rat model of partial carotid artery ligation
Q33677854A prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions: design and statistical methods of the PERSEUS clinical program
Q35028726A prospective, multicenter, post marketing surveillance study to evaluate the safety and effectiveness of the Superia-Sirolimus Eluting Coronary Stent System (SSECSS) implanted during routine clinical practice in India
Q37329589A prospective, randomized comparison of promus everolimus-eluting and TAXUS Liberte paclitaxel-eluting stent systems in patients with coronary artery disease eligible for percutaneous coronary intervention: the PROMISE study
Q41347740A randomized multicenter trial comparing the XIENCE everolimus eluting stent with the CYPHER sirolimus eluting stent in the treatment of female patients with de novo coronary artery lesions: The SPIRIT WOMEN study
Q40105594A randomized, controlled, multicenter trial to evaluate the safety and efficacy of Zotarolimus- vs. Paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries: five-year results from the ZOMAXX I trial
Q39121911A rare and serious unforeseen complication of cutting balloon angioplasty
Q55424383A rare complication of percutaneous coronary intervention: Coronary pseudoaneurysm formation.
Q37357342A review of current devices and a look at new technology: drug-eluting stents
Q42180347Accelerated Recovery of Endothelium Function after Stent Implantation with the Use of a Novel Systemic Nanoparticle Curcumin
Q46228970Acrylic copolymers as candidates for drug-eluting coating of vascular stents
Q46827359Acute thrombosis of a mesenteric artery drug-eluting stent following clopidogrel cessation
Q90354205Additional postdilatation using noncompliant balloons after everolimus-eluting stent implantation: Results of the PRESS trial
Q36398733Adjunctive balloon postdilatation after stent deployment: is it still necessary with drug-eluting stents?
Q36680683Adjunctive pharmacotherapy for coronary interventions-time to read the writing on the wall
Q58549172Advanced Glycation End Products:Receptors for Advanced Glycation End Products Axis in Coronary Stent Restenosis: A Prospective Study
Q98771885Advances in IVUS/OCT and Future Clinical Perspective of Novel Hybrid Catheter System in Coronary Imaging
Q28181298Advances in adjunctive pharmacological therapy for percutaneous coronary interventions
Q36046070Advances in nuclear imaging for preoperative risk assessment
Q84140501Advances in percutaneous coronary intervention
Q28972437Advances in stent technologies and their effect on clinical efficacy and safety
Q37866105Advantages and disadvantages of biodegradable platforms in drug eluting stents
Q51065281Adverse clinical events in patients treated with sirolimus-eluting stents: the impact of Type D personality.
Q91768223An abluminal biodegradable polymer sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients undergoing coronary revascularization: 3-year clinical outcomes of a randomized non-inferiority trial
Q36086606An evidence-based approach to the use of drug-eluting stents in clinical practice
Q36614126An overview of the TAXUS Express, paclitaxel-eluting stent clinical trial program
Q51192886Analysis of location and pattern of target vessel failure in chronic total occlusions after stent implantation and its potential for the efficient use of drug-eluting stents.
Q50990628Angiographic and 3D intravascular ultrasound assessment of overlapping bare metal stent and three different formulations of drug-eluting stents in patients with diabetes mellitus.
Q37347986Angiographic and clinical comparison of novel Orsiro Hybrid sirolimus-eluting stents and Resolute Integrity zotarolimus-eluting stents in all-comers with coronary artery disease (ORIENT trial): study protocol for a randomized controlled trial
Q53153267Angiographic patterns of in-stent restenosis classified by computed tomography in patients with drug-eluting stents: correlation with invasive coronary angiography.
Q37435155Angiographic results of the cobalt chromium Vision and Mini-Vision stents
Q38118943Angioplasty guided by intravascular ultrasound: meta-analysis of randomized clinical trials
Q28251955Angiotensin antagonism in coronary artery disease: results after coronary revascularisation
Q37664434Anti-CD133 antibody immobilized on the surface of stents enhances endothelialization.
Q37695396Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable Sn 2 taxane phospholipid prodrug using α(v)β₃-targeted theranostic nanoparticles.
Q37109628Anti-atherosclerotic and anti-diabetic properties of probucol and related compounds
Q36635049Anti-inflammatory effects of arsenic trioxide eluting stents in a porcine coronary model
Q52593614Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma.
Q93379484Antiplatelet agents in uncertain clinical scenarios-a bleeding nightmare
Q39498712Antiplatelet therapy after coronary stenting
Q28195049Antiplatelet therapy after percutaneous coronary intervention
Q36917389Antiplatelet therapy in patients undergoing coronary stenting: The risk of late stent thrombosis
Q36941850Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives
Q44993846Antiproliferative drug-eluting stents: systematic review of the benefits and estimate of economic impact
Q41989723Application of rotational atherectomy in the drug-eluting stent era.
Q43046506Attending to links in the safety chain for drug-eluting stents
Q37362731Avoiding restenosis: is there a role for glucocorticoids in the drug-eluting stent era?
Q51120123BRAVO I: A pilot study of vascular brachytherapy in polytetrafluoroethylene dialysis access grafts.
Q38036346Back to the future: how biology and technology could change the role of PTFE grafts in vascular access management
Q85555592Bare Metal Stents Versus Drug Eluting Stents: Where Do We Stand in 2015?
Q37502920Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis
Q37906371Bare-metal stents versus drug-eluting stents for primary angioplasty: long-term outcome
Q33833003Bayesian design of noninferiority trials for medical devices using historical data
Q39550187Berberine cooperates with adrenal androgen dehydroepiandrosterone sulfate to attenuate PDGF-induced proliferation of vascular smooth muscle cell A7r5 through Skp2 signaling pathway
Q28576577Berberine suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular smooth muscle cell regrowth after in vitro mechanical injury
Q38381158Beyond restenosis: Patients' preference for drug eluting or bare metal stents
Q38059840Biodegradable versus durable polymer drug eluting stents in coronary artery disease: insights from a meta-analysis of 5,834 patients.
Q45964336Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial.
Q46395870Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial
Q35939015Biomimetic actuators: where technology and cell biology merge
Q39097196Bioresorbable Scaffolds for Coronary Artery Disease
Q28076491Bioresorbable Scaffolds: Current Evidences in the Treatment of Coronary Artery Disease
Q36055029Bioresorbable Stents in PCI.
Q38105546Bioresorbable scaffolds in the treatment of coronary artery disease
Q26766579Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention
Q27690259Bioresorbable scaffolds: rationale, current status, challenges, and future
Q36040667Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies
Q47296986Blinded sample size recalculation in clinical trials with binary composite endpoints
Q30667055Borderline trend towards long-term mortality benefit from drug eluting stents implantation in ST-elevation myocardial infarction patients in Poland-data from NRDES registry.
Q35291798Bridging therapy for early surgery in patients on dual antiplatelet therapy after drug-eluting stent implantation
Q47381152Carbon-coated stents in patients with acute coronary syndromes
Q51558606Cardiac revascularization--a need for independent decision-makers.
Q55260543Cardiovascular Outcomes in Patients on Hemodialysis following Drug-Eluting versus Bare-Metal Coronary Stents.
Q38381419Causes, assessment, and treatment of stent thrombosis--intravascular imaging insights
Q40388668Characterization of Porous TiO2 Surfaces Formed on 316L Stainless Steel by Plasma Electrolytic Oxidation for Stent Applications
Q39628078Choice of stent and outcomes after treatment of drug-eluting stent restenosis in highly complex lesions
Q38194095Choosing the right coronary stent in the modern era.
Q34981550Circulating fibroblast growth factor 23 is associated with angiographic severity and extent of coronary artery disease
Q33770283Clinical Implication of Optical Coherence Tomography-Based Neoatherosclerosis
Q37647406Clinical Outcomes in Diabetic Patients Who Underwent Percutaneous Coronary Intervention during the Plain Old Balloon Angioplasty (POBA)-, Bare Metal Stents (BMS)- and Drug-eluting Stents (DES)-eras from 1984 to 2010.
Q47131283Clinical and Angiographic Outcomes of the First Korean-made Sirolimus-Eluting Coronary Stent with Abluminal Bioresorbable Polymer
Q43015474Clinical and angiographic outcomes of drug-eluting stents in patients with large vessel and single coronary artery lesion.
Q47791469Clinical and angiographic results of angioplasty with a paclitaxel-eluting stent for unprotected left main coronary artery disease (a study of 101 consecutive patients).
Q33437306Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry
Q51809654Clinical effects of routine postdilatation of drug-eluting stents.
Q47778717Clinical impact of drug-eluting stents in an unselected population of diabetic patients.
Q57566896Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial
Q36528924Clinical outcomes between different stent designs with the same polymer and drug: comparison between the Taxus Express and Taxus Liberte stents
Q84326034Clinical outcomes for single stent and multiple stents in contemporary practice
Q36602870Clinical outcomes in 995 unselected real-world patients treated with an ultrathin biodegradable polymer-coated sirolimus-eluting stent: 12-month results from the FLEX Registry.
Q38630250Clinical outcomes of biodegradable polymer biolimus-eluting BioMatrix stents versus durable polymer everolimus-eluting Xience stents.
Q41486927Clinical outcomes of real-world patients treated with an amphilimus polymer-free stent versus new generation everolimus-eluting stents.
Q37388164Clinical outcomes with Biolimus (A9)™ eluting stent, 'BioMatrix' in diabetic patients--interim results from multicenter post market surveillance registry in India
Q46358322Clinical results of drug eluting stents compared to bare metal stents for patients with ST elevation acute myocardial infarction
Q35879094Clinical trials in restenosis with 7-hexanoyltaxol and paclitaxel-eluting stents
Q28219418Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI)
Q42623179Clinical usefulness of the Driver(®) stent in a retrospective, collaborative, multicenter, open-label study in Japanese real-world patients with coronary artery disease and the drug-eluting stent era.
Q37209003Clopidogrel and coronary stents: risks and benefits
Q28199126Clopidogrel treatment surrounding percutaneous coronary intervention: when should it be started and stopped?
Q40393685Clopidogrel: cardiologists' panacea or neurologists' headache?
Q30573045Clopidogrel: the data, the experience, and the controversies
Q43179050Combined drug release from biodegradable bilayer coating for endovascular stents
Q39334521Combined paclitaxel-eluting balloon and Genous cobalt-chromium alloy stent utilization in de novo coronary stenoses (PEGASUS).
Q37594516Comparative Study between Perfusion Changes and Positive Findings on Coronary Flow Reserve
Q34888771Comparative effectiveness of drug-eluting stents on long-term outcomes in elderly patients treated for in-stent restenosis: a report from the National Cardiovascular Data Registry
Q46732330Comparative endoluminal visualization of TAXUS crush-stenting at 9 months follow-up by intravascular ultrasound and optical coherence tomography
Q46583403Comparative study of tacrolimus and paclitaxel stent coating in the porcine coronary model
Q28551554Comparing the Clinical Outcomes between Drug Eluting Stents and Bare Metal Stents in Patients with Insulin-Treated Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials
Q58268606Comparing the use of cobalt chromium stents to stainless steel stents in primary percutaneous coronary intervention for acute myocardial infarction: A prospective registry
Q28468709Comparison of Bare-Metal Stent and Drug-Eluting Stent for the Treatment of Patients Undergoing Percutaneous Coronary Intervention for Unprotected Left Main Coronary Artery Disease - Long-Term Result from a Single Center Experience
Q37590761Comparison of Clinical Outcomes in Patients Undergoing Coronary Intervention with Drug-Eluting Stents or Bare-Metal Stents: A Nationwide Population Study.
Q36992991Comparison of Drug-eluting Coronary Stents, Bare Coronary Stents and Self-expanding Stents in Angioplasty of Middle Cerebral Artery Stenoses
Q39238408Comparison of Vascular Responses Following New-Generation Biodegradable and Durable Polymer-Based Drug-Eluting Stent Implantation in an Atherosclerotic Rabbit Iliac Artery Model
Q36291363Comparison of bare-metal stents and drug-eluting stents in coronary ostial lesions (from the National Heart, Lung, and Blood Institute Dynamic Registry).
Q37466710Comparison of coronary DES and BMS in octogenarians: A systematic review and meta-analysis
Q92977964Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis
Q37588855Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial
Q87403678Comparison of first- and second-generation drug-eluting stent efficacies for treating left main and/or three-vessel disease: a propensity matched study
Q40699215Comparison of long-term in-stent vascular response between abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent: 3-year OCT follow-up from the TARGET I trial
Q43235841Comparison of long-term outcomes following sirolimus-eluting stent vs paclitaxel-eluting stent implantation in patients with long calcified coronary lesions
Q39717689Comparison of long-term outcomes of bare-metal and paclitaxel-eluting stents in New York
Q37098303Comparison of one-year clinical outcomes with paclitaxel-eluting stents versus bare metal stents in everyday practice
Q35932110Comparison of optical coherence tomographic assessment between first- and second-generation drug-eluting stents
Q28219874Comparison of outcomes of percutaneous coronary intervention on proximal versus non-proximal left anterior descending coronary artery, proximal left circumflex, and proximal right coronary artery: a cross-sectional study
Q37445290Comparison of sirolimus and paclitaxel-eluting stents for complex coronary lesions: an intravascular ultrasound study.
Q53396688Comparison of the efficacy and safety of paclitaxel-eluting coroflex please stents and paclitaxel-eluting stents in patients with coronary artery disease: a randomized PIPA trial.
Q51097849Comparison of the slow-release polymer-based paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions.
Q35831446Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial
Q34431992Comparison of zotarolimus-eluting and sirolimus-eluting coronary stents: a study from the Western Denmark Heart Registry
Q53170857Comparisons of everolimus and Paclitaxel-eluting stents in patients with acute myocardial infarction.
Q36095492Complete myocardial revascularization: between myth and reality
Q37768719Computational structural modelling of coronary stent deployment: a review
Q36495111Computerized two-lead resting ECG analysis for the detection of coronary artery stenosis after coronary revascularization
Q82905497Concurrent drug eluting/bare metal stent implantation during percutaneous coronary intervention in target vessel: outcomes and 1-year follow-up
Q89842792Conditional power analysis of the DEBUT trial - Authors' reply
Q56384060Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease
Q41994984Contact lenses for ophthalmic drug delivery
Q26795703Contact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery
Q64924246Contemporary Use of Drug-eluting Stents.
Q38591868Continuation of Dual-Antiplatelet Therapy Following Percutaneous Revascularization with a Drug-Eluting Stent: What Duration Is Optimal?
Q38543392Controlling drug delivery from coronary stents: are we aiming for the right targets?
Q38079934Controversies in the use & implementation of drug-eluting stent technology.
Q50944381Controversies surrounding the use of drug-eluting stents.
Q51065465Coronary artery bypass surgery versus percutaneous coronary intervention with drug-eluting stent implantation in patients with multivessel coronary disease.
Q51321265Coronary artery calcification as a new predictor of non-target lesion revascularization during the chronic phase after successful percutaneous coronary intervention.
Q35193488Coronary artery disease in type 2 diabetes mellitus: Recent treatment strategies and future perspectives
Q40693886Coronary artery overexpansion increases neointimal hyperplasia after stent placement in a porcine model
Q36569798Coronary artery restenosis: vascular biology and emerging therapeutic strategies
Q38109113Coronary drug-eluting stents: from design optimization to newer strategies
Q49948954Coronary plaque characteristics on baseline CT predict the need for late revascularization in symptomatic patients after percutaneous intervention.
Q35189881Coronary revascularization trends in the United States, 2001-2008.
Q38009703Coronary stent choice in patients with acute myocardial infarction
Q46920107Coronary stent imaging with dual-source CT: assessment of lumen visibility using different convolution kernels and postprocessing filters
Q53433469Coronary stent occlusion: reverse attenuation gradient sign observed at computed tomography angiography improves diagnostic performance.
Q36514842Coronary stent thrombosis: current insights into new drug-eluting stent designs
Q37121422Coronary stent thrombosis: what have we learned?
Q43250825Coronary stenting with the sirolimus-eluting stent in patients with restenosis after intracoronary brachytherapy: results from the prospective multicentre German Cypher Stent Registry
Q38093501Coronary stents: historical development, current status and future directions
Q46137918Correlation between quantitative angiographic and intravascular ultrasound parameters in patients treated with sirolimus analogous-eluting stents
Q36703074Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial
Q34669846Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents in patients with multivessel coronary artery disease compared to coronary artery bypass surgery five-years after intervention.
Q40375049Cost-effectiveness of primary percutaneous coronary intervention versus thrombolytic therapy for acute myocardial infarction
Q46921049Cost-effectiveness of the Taxus paclitaxel-eluting stent in the Swedish healthcare system
Q38224405Current and future perspectives on drug-eluting bioresorbable coronary scaffolds
Q37125540Current status of off-pump coronary artery bypass surgery
Q37799356Current status of the Xience V® everolimus-eluting coronary stent system.
Q45004986Cypher stent: the German registry. Results of the German prospective multicenter registry on Cypher
Q36335170Cypher versus taxus: are there differences?
Q37749818Decision-making: stenting in acute myocardial infarction
Q44763980Decreased risk of stent fracture-related restenosis between paclitaxel-eluting stents and sirolimus eluting stents: results of long-term follow-up
Q64058860Delivery of Cell-Specific Aptamers to the Arterial Wall with an Occlusion Perfusion Catheter
Q34349030Delivery of plasmid DNA to vascular tissue in vivo using catheter balloons coated with polyelectrolyte multilayers
Q91588188Developing and Testing a Personalized, Evidence-Based, Shared Decision-Making Tool for Stent Selection in Percutaneous Coronary Intervention Using a Pre-Post Study Design
Q37768165Development and performance of the zotarolimus-eluting Endeavor coronary stent
Q36333923Diabetes and percutaneous coronary intervention in the setting of an acute coronary syndrome
Q41608247Diagnosis and management challenges of in-stent restenosis in coronary arteries
Q50979928Diagnostic accuracy of 64-slice CT in the assessment of coronary stents.
Q33551242Diagnostic accuracy of 64-slice computed tomography coronary angiography for the detection of in-stent restenosis: a meta-analysis
Q28552391Dialysis Patients with Implanted Drug-Eluting Stents Have Lower Major Cardiac Events and Mortality than Those with Implanted Bare-Metal Stents: A Taiwanese Nationwide Cohort Study
Q53598172Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial.
Q51355090Diphenylalanine peptide nanotubes self-assembled on functionalized metal surfaces for potential application in drug-eluting stent.
Q36232816Direct stenting with sirolimus-eluting stents
Q24306656Disruption of platelet-derived growth factor-dependent phosphatidylinositol 3-kinase and phospholipase Cγ 1 activity abolishes vascular smooth muscle cell proliferation and migration and attenuates neointima formation in vivo
Q36345131Distinctive effects of CD34- and CD133-specific antibody-coated stents on re-endothelialization and in-stent restenosis at the early phase of vascular injury
Q51520186Do drug-eluting stents mark the end of coronary artery bypass surgery?
Q37941867Do statins have a role in reduction/prevention of post-PCI restenosis?
Q36997203Does the use of paclitaxel or rapamycin-eluting stent decrease further need for coronary-artery bypass grafting when compared with bare-metal stent?
Q51484880Dollars and stents: the economics of drug-eluting stents.
Q36815941Drug delivery via nano-, micro and macroporous coronary stent surfaces.
Q36812894Drug eluting stents for ST-elevation myocardial infarction: risk and benefit
Q36282710Drug eluting stents: an updated meta-analysis of randomised controlled trials
Q37853958Drug eluting versus bare metal stents in cardiac allograft vasculopathy: a systematic review of literature
Q84982962Drug-Eluting Stents Are Not Indicated for Patients With Acute Coronary Syndrome - Should Drug-Eluting Stents Be Indicated for Patients With Acute Coronary Syndrome? (Con) -
Q92189331Drug-coated Balloons for Small Coronary Vessel Interventions: A Literature Review
Q38241038Drug-coated balloon angioplasty for drug-eluting stent restenosis: insight from randomized controlled trials
Q92781182Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial
Q38028877Drug-coated balloons for coronary and peripheral interventional procedures
Q45057770Drug-coated stents. Where do we stand in 2004?
Q37902075Drug-eluting Stents in Acute Coronary Syndrome: Is There a Risk of Stent Thrombosis with Second-Generation Stents?
Q38818530Drug-eluting balloon versus bare-mental stent and drug-eluting stent for de novo coronary artery disease: A systematic review and meta-analysis of 14 randomized controlled trials
Q38037077Drug-eluting coronary stents - focus on improved patient outcomes
Q48028885Drug-eluting coronary stents: as safe as bare-metal stents, but optimized antiplatelet therapy may further improve clinical outcome
Q37668357Drug-eluting stent coatings
Q48015888Drug-eluting stent in diabetes
Q37329149Drug-eluting stent safety: findings from preclinical studies
Q50944371Drug-eluting stent thrombosis vs bare metal stent restenosis: finding the lesser of two evils.
Q34091036Drug-eluting stents
Q45287552Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial
Q37078803Drug-eluting stents for left main coronary artery stenosis: case selection and technical issues
Q38653405Drug-eluting stents in clinical routine: a 1-year follow-up analysis based on German health insurance administrative data from 2008 to 2014.
Q38966141Drug-eluting stents in patients with anterior STEMI undergoing primary angioplasty: a substudy of the DESERT cooperation.
Q28476360Drug-eluting stents in patients with chronic kidney disease: a prospective registry study
Q37577872Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment
Q37788985Drug-eluting stents in the elderly
Q38262150Drug-eluting stents in unprotected left main coronary artery disease
Q41836503Drug-eluting stents not for all patients
Q51036741Drug-eluting stents versus bare metal stents following rotational atherectomy for heavily calcified coronary lesions: late angiographic and clinical follow-up results.
Q24186681Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes
Q24235466Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes
Q57389444Drug-eluting stents versus bare-metal stents for acute coronary syndrome
Q38612419Drug-eluting stents versus bare-metal stents for acute coronary syndrome.
Q37206911Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis
Q35945466Drug-eluting stents: a mechanical and pharmacologic approach to coronary artery disease
Q45190838Drug-eluting stents: are they really safe?
Q50944368Drug-eluting stents: can we move beyond stent thrombosis?
Q46395865Drug-eluting stents: is new necessarily better?
Q45121023Drug-eluting stents: some bare facts
Q38344198Drug-eluting stents: the past, present, and future.
Q38162864Drug-eluting versus bare-metal coronary stents: where are we now?
Q36350819Drug-eluting versus third-generation bare metal stents: the US strategy
Q36040853Drugs to suppress cough
Q38635747Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies
Q38692636Dual Antiplatelet Therapy in Patients with Stable Ischemic Heart Disease
Q40563215Dual antiplatelet therapy can be discontinued at three months after implantation of zotarolimus-eluting stent in patients with coronary artery disease
Q37953153Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: a review of the current guidelines and literature.
Q26830266Duration of dual antiplatelet treatment in the era of next generation drug-eluting stents
Q31102731Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study
Q37397071Early clinical outcomes of primary percutaneous coronary intervention in bharatpur, Nepal
Q37112395Early restenosis after drug-eluting stent implantation: A putative role for platelet activation
Q47696178Editor's note: on global informing
Q90466540Editorial: Remaining issue after drug-eluting stent implantation: Histopathological mechanisms of early-phase in-stent restenosis
Q42917980Effect of Coronary Target Lesion Revascularization on Late Cardiac Events After Insertion of Sirolimus-Eluting or Bare Metal Stents
Q46701610Effect of Paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in Korean diabetic patients
Q37435145Effect of atorvastatin-eluting stents in a rabbit iliac artery restenosis model
Q28219713Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study
Q53535880Effect of exercise-based cardiac rehabilitation on non-culprit mild coronary plaques in the culprit coronary artery of patients with acute coronary syndrome.
Q30397835Effect of intravascular ultrasound-guided adjuvant high-pressure non-compliant balloon post-dilation after drug-eluting stent implantation
Q84183395Effect of stent thrombosis on the risk-benefit balance of drug-eluting stents and bare metal stents
Q34753360Effectiveness of drug-eluting stents versus bare-metal stents in large coronary arteries in patients with acute myocardial infarction
Q28476506Effects of an alpha-4 integrin inhibitor on restenosis in a new porcine model combining endothelial denudation and stent placement
Q53384415Effects of celecoxib on restenosis after coronary intervention and evolution of atherosclerosis (Mini-COREA) trial: celecoxib, a double-edged sword for patients with angina.
Q34452943Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis
Q46663848Effects of drug-eluting stents on systemic inflammatory response in patients with unstable angina pectoris undergoing percutaneous coronary intervention
Q37413031Efficacies of the new paclitaxel-eluting Coroflex Please stent in percutaneous coronary intervention; comparison of efficacy between Coroflex Please and Taxus (ECO-PLEASANT) trial: study rationale and design.
Q36688217Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial
Q64057487Efficacy and safety of drug-eluting stenting compared with bypass grafting in diabetic patients with multivessel and/or left main coronary artery disease
Q36639071Efficacy and safety of drug-eluting stents: current best available evidence
Q43128990Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial
Q35771807Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials
Q44850925Efficacy of dual antiplatelet therapy combined with Naoxintong capsules [see text] following coronary microembolization induced by homologous microthrombi in rats
Q33949407Efficacy of sirolimus-eluting stents compared with paclitaxel-eluting stents in an unselected population with coronary artery disease: 24-month outcomes of patients in a prospective non-randomized registry in Southern Turkey.
Q84889727Emergent coronary artery bypass grafting for cardiogenic shock caused by very late drug-eluting stent thrombosis
Q41412020Emodin prevents intima thickness via Wnt4/Dvl-1/β-catenin signaling pathway mediated by miR-126 in balloon-injured carotid artery rats
Q42008887Endothelial cell repopulation after stenting determines in-stent neointima formation: effects of bare-metal vs. drug-eluting stents and genetic endothelial cell modification
Q38297800Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration
Q37880131Endovascular management of vertebral artery disease.
Q51345743Endovascular reconstruction by means of stent placement in symptomatic intracranial atherosclerotic stenosis.
Q34373214Evaluating the effectiveness of a rapidly adopted cardiovascular technology with administrative data: the case of drug-eluting stents for acute coronary syndromes
Q35230526Evaluation of clinical outcomes in patients undergoing dual vessel percutaneous coronary intervention using sirolimus-eluting coronary stent system in India.
Q83014349Evaluation of in-stent neointimal tissue components using integrated backscatter intravascular ultrasound: comparison of drug-eluting stents and bare-metal stents
Q36206234Evaluation of the efficacy of paclitaxel with curcumin combination in ovarian cancer cells
Q37196027Event detection using population-based health care databases in randomized clinical trials: a novel research tool in interventional cardiology
Q91611699Everolimus-Eluting Second-Generation Stents for Treatment of De Novo Lesions in Patients with Cardiac Allograft Vasculopathy
Q24630321Everolimus-eluting stents in interventional cardiology
Q42912237Everolimus-eluting stents: insights from the SPIRIT IV and COMPARE trials
Q38037072Everolimus-eluting stents: update on current clinical studies
Q44317798Evolution of stents: past, present and future
Q46293725Extended follow-up following "full-metal jacket" percutaneous coronary interventions with drug-eluting stents
Q36925442External adjustment sensitivity analysis for unmeasured confounding: an application to coronary stent outcomes, Pennsylvania 2004-2008.
Q47655289Extracellular Matrix Proteomics Reveals Interplay of Aggrecan and Aggrecanases in Vascular Remodeling of Stented Coronary Arteries
Q37016139FDA advisory panel on the safety and efficacy of drug-eluting stents: summary of findings and recommendations
Q35049945Fabrication of nonbiofouling metal stent and in vitro studies on its hemocompatibility
Q51810171Finite element analysis of balloon-expandable coronary stent deployment: influence of angioplasty balloon configuration.
Q90095042First clinical evidence characterizing safety and efficacy of the new CoCr Biolimus-A9 eluting stent: The Biomatrix Alpha™ registry
Q51541952First-in-human testing of a wirelessly controlled drug delivery microchip.
Q45036826Five-year clinical follow-up of a randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus (LIPSIA Yukon trial).
Q43685995Five-year clinical outcome of titanium-nitride-oxide-coated bioactive stent implantation in a real-world population: a comparison with paclitaxel-eluting stents: the PORI registry.
Q40832041Five-year clinical outcomes of drug-eluting stents according to on-label and off-label use.
Q34804267Fusion of 3D QCA and IVUS/OCT.
Q45865166Gene therapy and stem cell therapy for cardiovascular diseases today: a model for translational research
Q36839653Glucocorticoids in the prevention of restenosis after coronary angioplasty: therapeutic potential
Q46782423Glucose metabolism
Q28239975Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology
Q50930160High frequency of contact allergy to gold in patients with endovascular coronary stents.
Q33958472Highly selective and sensitive assay for paclitaxel accumulation by tumor cells based on selective solid phase extraction and micro-flow liquid chromatography coupled to mass spectrometry
Q36261625Histological validation of frequency domain optical coherence tomography for the evaluation of neointimal formation after a novel polymer-free sirolimus-eluting stent implantation
Q38235226Histopathology of vascular response to drug-eluting stents: an insight from human autopsy into daily practice
Q59355879How and When to Decide on Revascularization in Stable Ischemic Heart Disease
Q36441977How to revascularize patients with diabetes mellitus: bypass or stents and drugs?
Q39398196Hydroxyapatite-polymer biocomposites for bone regeneration: A review of current trends
Q37781241ISAR - A Story of Trials With Impact on Practice -
Q40901351Immediate and Six-month Clinical Outcome of Percutaneous Coronary Intervention in a Tertiary Hospital in the Sultanate of Oman.
Q47623838Immediate procedural and long-term clinical outcomes following drug-eluting stent implantation to ostial saphenous vein graft lesions
Q33427823Impact of Anemia and Dual Antiplatelet Therapy on Mortality in Patients Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents
Q42690175Impact of Paclitaxel-Eluting Balloons Compared to Second-Generation Drug-Eluting Stents for of In-Stent Restenosis in a Primarily Acute Coronary Syndrome Population
Q47623826Impact of abciximab on coronary restenosis in diabetic patients undergoing elective paclitaxel-eluting stent implantation. A prospective, randomized, placebo-controlled study
Q55057793Impact of body fat distribution on long-term clinical outcomes after drug-eluting stent implantation.
Q40117934Impact of coronary artery calcification in percutaneous coronary intervention with paclitaxel-eluting stents: Two-year clinical outcomes of paclitaxel-eluting stents in patients from the ARRIVE program
Q36720378Impact of diabetes on long-term outcome after primary angioplasty: insights from the DESERT cooperation
Q84919676Impact of diabetes on long-term outcome in STEMI patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors and BMS or DES
Q44964313Impact of duration of clopidogrel prescription on outcome of DES as compared to BMS in primary angioplasty: a meta-regression analysis of randomized trials
Q50100183Impact of previous drug-eluting stent restenosis in non-left main coronary artery lesions on long-term outcomes after left main coronary artery stenting: an observation from the AOI-LMCA registry.
Q51673723Impact of stent length on clinical outcomes of first-generation and new-generation drug-eluting stents.
Q47228855Impact of vessel size, lesion length and diabetes mellitus on angiographic restenosis outcomes: insights from the NIRTOP study
Q35773286Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study
Q64119803Improving the anti-keloid outcomes through liposomes loading paclitaxel-cholesterol complexes
Q83424219In vitro and in vivo evaluation of the safety and stability of the TAXUS Paclitaxel-Eluting Coronary Stent
Q53233760In vivo evaluation of stent patency by 64-slice multidetector CT coronary angiography: shall we do it or not?
Q44668746In-hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: a report from the EVENT registry
Q37677351In-hospital and mid-term adverse clinical outcomes of a direct stenting strategy versus stenting after pre-dilatation for the treatment of coronary artery lesions
Q38135896In-stent restenosis of drug-eluting stents.
Q39766893In-stent thrombosis after 68 months of implantation inspite of continuous dual antiplatelet therapy: a case report
Q38017707In-vitro dissolution methods for controlled release parenterals and their applicability to drug-eluting stent testing.
Q45843175Incidence of definite stent thrombosis or in-stent restenosis after drug-eluting stent implantation for treatment of coronary in-stent restenosis: from Western Denmark Heart Registry
Q54548046Incidence of periprocedural myocardial infarction following stent implantation: comparison between first- and second-generation drug-eluting stents.
Q46695761Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET).
Q48860243Influence of antiplatelet medications on bleeding events in hemodialysis patients.
Q47279348Influence of low-dose aspirin (81 mg) on the incidence of definite stent thrombosis in patients receiving bare-metal and drug-eluting stents
Q47804035Inhibition of neddylation by MLN4924 improves neointimal hyperplasia and promotes apoptosis of vascular smooth muscle cells through p53 and p62.
Q83371544Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter
Q38931805Inhibitory effects of roscovitine on proliferation and migration of vascular smooth muscle cells in vitro
Q44589935Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a r
Q37703974Interventional Revascularization of Coronary Artery Lesions in Diabetic Patients; In-hospital and One Year Follow up
Q37108320Intimal hyperplasia in murine models
Q51659927Intracoronary brachytherapy for in-stent restenosis: will it remain a viable therapy?
Q37306731Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury
Q39313882Intravascular imaging comparison of two metallic limus-eluting stents abluminally coated with biodegradable polymers: IVUS and OCT results of the DESTINY trial
Q90479896Intravascular ultrasound versus angiography-guided drug-eluting stent implantation in patients with complex coronary lesions: An updated meta-analysis of nine randomized clinical trials
Q82371928Intravascular ultrasound-guided primary percutaneous coronary intervention with drug-eluting stent implantation in patients with ST-segment elevation myocardial infarction
Q39423831Investigation of PLLA/PCL blends and paclitaxel release profiles
Q35584070Is routine stenting for acute myocardial infarction superior to balloon angioplasty? A randomised comparison in a large cohort of unselected patients
Q44766507Is systematic use of drug-eluting stents justified? Arguments against
Q36412659Is there an alternative to systemic anticoagulation, as related to interventional biomedical devices?
Q43012238Is there any place for oral anti-restenotic treatment in the era of drug eluting stents?
Q47586721Late adverse events after drug-eluting stent implantation
Q42832154Late angiographic stent thrombosis of polymer based paclitaxel eluting stent
Q47795262Late angiographic stent thrombosis: the LAST straw for drug-eluting stents?
Q43937843Late catch-up phenomenon associated with stent fracture after sirolimus-eluting stent implantation: incidence and outcome
Q35582676Late incomplete lesion coverage following Cypher stent deployment for diffuse right coronary artery stenosis
Q34179087Late outcomes following percutaneous coronary interventions: results from a large, observational registry
Q42859896Late stent thrombosis after drug-eluting stent implantation: a rare case of accelerated neo-atherosclerosis and early manifestation of neointimal rupture
Q38023285Late stent thrombosis: the last remaining obstacle in coronary interventional therapy
Q50859001Late thrombosis with drug-eluting stents: anatomy of a controversy and lessons learned.
Q39770648Liposomal simvastatin attenuates neointimal hyperplasia in rats.
Q51687284Local Stent-Based Release of Transforming Growth Factor-β1 Limits Arterial In-Stent Restenosis.
Q37765610Local drug delivery for treatment of coronary and peripheral artery disease
Q43835460Long term follow-up of drug eluting versus bare metal stents in the treatment of saphenous vein graft lesions
Q39917344Long-Term Predictors of Clinical Events after Off-Label Use of Drug-Eluting Stent beyond 1 Year
Q43282873Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial
Q82071524Long-term (≥2 years) follow-up optical coherence tomographic study after sirolimus- and paclitaxel-eluting stent implantation: comparison to 9-month follow-up results
Q83945566Long-term clinical efficacy of cutting balloon angioplasty followed by bare metal stent implantation for treating ostial left anterior descending artery lesions
Q45082711Long-term clinical follow-up after drug-eluting stent implantation for bare metal in-stent restenosis.
Q51524387Long-term clinical outcome of thin-strut cobalt-chromium stents in the drug-eluting stent era: results of the COBALT (comparison of bare-metal stents in all-comers' lesion treatment) registry.
Q45409899Long-term clinical outcomes of drug-eluting stents vs bare-metal stents in Chinese patients.
Q37466704Long-term clinical outcomes of drug-eluting stents vs. bare-metal stents in Chinese geriatric patients.
Q26767320Long-term clinical outcomes of everolimus-eluting stent versus paclitaxel-eluting stent in patients undergoing percutaneous coronary interventions: a meta-analysis
Q46942290Long-term follow-up after coronary stenting with the sirolimus-eluting stent in clinical practice: results from the prospective multi-center German Cypher Stent Registry
Q34024602Long-term follow-up results in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents: results from a single high-volume PCI centre
Q53074100Long-term outcome after drug-eluting stent implantation in comparison with bare metal stents: a single centre experience.
Q83163597Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with diabetes mellitus: a patient-level meta-analysis of randomized trials
Q51187551Long-term outcome of drug-eluting stenting for stenoses of the intracranial vertebrobasilar artery and vertebral ostium.
Q37074525Long-term outcomes after a strategy of percutaneous coronary intervention of the infarct-related artery with drug-eluting stents or bare metal stents vs medical therapy alone in the Occluded Artery Trial (OAT).
Q39945931Long-term outcomes following drug-eluting stents versus bare metal stents for primary percutaneous coronary intervention: A real-world analysis of 11,181 patients from the british columbia cardiac registry
Q37598827Long-term outcomes of intravascular ultrasound-guided implantation of bare metal stents versus drug-eluting stents in primary percutaneous coronary intervention
Q37052543Long-term outcomes of patients receiving drug-eluting stents
Q33776103Long-term outcomes with paclitaxel-eluting stents versus bare metal stents in everyday practice: a Canadian experience
Q37121431Long-term performance of the second-generation cobalt-chromium sirolimus-eluting stents in real-world clinical practice: 3-year clinical outcomes from the prospective multicenter FOCUS registry
Q38153786Long-term safety of drug-eluting stents
Q51549230Looking for the culprit of coronary in-stent restenosis: debatable role for the fibrinolytic system?
Q37858604Low stent thrombosis risk with the XIENCE V® Everolimus-Eluting Coronary Stent: evidence from randomized and single-arm clinical trials
Q39188081Low-dose paclitaxel modulates tumour fibrosis in gastric cancer
Q56341960L’angioplastie du tronc commun non protégé de l’artère coronaire gauche: devenir des patients à court et moyen termes
Q37726055MAD (multiagent delivery) nanolayer: delivering multiple therapeutics from hierarchically assembled surface coatings
Q38154806Macroscale delivery systems for molecular and cellular payloads.
Q38082646Management of cardiovascular disease in patients with kidney disease
Q36837612Mechanical and Histopathological Comparison between Commercialized and Newly Designed Coronary Bare Metal Stents in a Porcine Coronary Restenosis Model
Q83181418Medical and Catheter-Based Therapies for Managing Stable Coronary Disease: Lessons From the COURAGE Trial
Q56638730Medikamente freisetzende Koronarstents und mit Medikamenten beschichtete Ballonkatheter
Q46527895Meta-analysis shows similar risk of thrombosis after drug-eluting stent, bare-metal stent, or angioplasty
Q34304812Microelectromechanical systems and nanotechnology: a platform for the next stent technological era.
Q48097275Mid-to-long term mortality following surgical versus percutaneous coronary revascularization stratified according to stent subtype: An analysis of 6,682 patients with multivessel disease
Q34167714Molecular imaging of drug-eluting coronary stents: method development, optimization and selected applications
Q46277755Monocyte-mediated drug delivery systems for the treatment of cardiovascular diseases
Q36779195Multilayered polyelectrolyte assemblies as platforms for the delivery of DNA and other nucleic acid-based therapeutics
Q35772244Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes
Q37188126Multivessel disease: percutaneous coronary intervention for classic coronary artery bypass grafting indications
Q37664872Nanoparticle shape improves delivery: rational coarse grain molecular dynamics (rCG-MD) of taxol in worm-like PEG-PCL micelles
Q28220309Nanoparticulate carriers for the treatment of coronary restenosis
Q55265918Nanosecond pulsed electric fields promoting the proliferation of porcine iliac endothelial cells: An in vitro study.
Q37844446Nanostructured polymer assemblies formed at interfaces: applications from immobilization and encapsulation to stimuli-responsive release
Q37789181Nanotechnology and its relationship to interventional radiology. Part II: Drug Delivery, Thermotherapy, and Vascular Intervention
Q26774540Neoatherosclerosis: Coronary stents seal atherosclerotic lesions but result in making a new problem of atherosclerosis
Q44672104Neointimal coverage and vasodilator response to titanium-nitride-oxide-coated bioactive stents and everolimus-eluting stents in patients with acute coronary syndrome: insights from the BASE-ACS trial
Q52643288Neointimal patterns obtained by optical coherence tomography correlate with specific histological components and neointimal proliferation in a swine model of restenosis.
Q83664512Neointimal tissue characteristics following sirolimus-eluting stent implantation: OCT quantitative tissue property analysis
Q45248786Neutropenia in patients treated with thienopyridines and high-dose oral prednisone after percutaneous coronary interventions
Q36654375New developments in coronary stent technology
Q36752088New percutaneous approaches for chronic total occlusion of coronary arteries
Q36160441New stent design for use in small coronary arteries during percutaneous coronary intervention
Q24642679Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V)
Q45340209Nine-month angiographic and intravascular ultrasound outcomes after resolute zotarolimus-eluting stent implantation for the treatment of in-stent restenosis
Q47224927Nine-month results of the BIOHELIX-I clinical trial study: Evaluation of the PRO-Kinetic Energy cobalt chromium bare-metal stent system.
Q37887771Nitric oxide: a guardian for vascular grafts?
Q39000577Nobori-Biolimus-Eluting Stents versus Resolute Zotarolimus-Eluting Stents in Patients Undergoing Coronary Intervention: A Propensity Score Matching
Q21562470Non thermal irreversible electroporation: novel technology for vascular smooth muscle cells ablation
Q24186673Non-acute percutaneous coronary intervention versus medical therapy in patients with ischaemic heart disease
Q49092553Novel Poly(Diol Sebacate)s as Additives to Modify Paclitaxel Release From Poly(Lactic-co-Glycolic Acid) Thin Films.
Q35997659Novel therapies for hemodialysis vascular access dysfunction: fact or fiction!
Q37269384Off-label use of stents: bare-metal versus drug-eluting stents
Q36614131Off-label use: an industry perspective on expanding use beyond approved indications
Q46102010On the ability of imatinib mesylate to inhibit smooth muscle cell proliferation without delaying endothelialization: an in vitro study
Q35820167On-label and off-label use of drug-eluting stents: comparison of short- and long-term outcomes
Q35584611One year clinical follow up of paclitaxel eluting stents for acute myocardial infarction compared with sirolimus eluting stents
Q39121381One-Year Outcome of Everolimus-Eluting Stents Versus Biolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention
Q37387136One-year clinical outcomes of BioMatrix™-Biolimus A9™ eluting stent: the e-BioMatrix multicenter post marketing surveillance registry in India
Q38052908One-year clinical outcomes of ultra long apollo polymer-based Paclitaxel-eluting stents in patients with complex, long coronary artery lesions
Q44818364Optical coherence tomographic comparison of neointimal coverage between sirolimus- and resolute zotarolimus-eluting stents at 9 months after stent implantation.
Q50437651Optical coherence tomography analysis of the stent strut and prediction of resolved strut malapposition at 3 months after 2nd-generation drug-eluting stent implantation.
Q37851899Optical coherence tomography endpoints in stent clinical investigations: strut coverage
Q54438512Optical coherence tomography findings of very late stent thrombosis after drug-eluting stent implantation.
Q26852812Optimal Duration of Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: Shorter or Longer?
Q38206844Optimal aspirin dose in acute coronary syndromes: an emerging consensus.
Q28173975Optimal duration of antiplatelet therapy in recipients of coronary drug-eluting stents
Q28217724Oral antiplatelet therapy and percutaneous coronary intervention
Q37397095Outcome and Predictors of Stent Thrombosis in the First Romanian Registry of Drug Eluting Stent (RODESINO EXTENSION)
Q36942534Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
Q42604179Outcomes of Patients Treated with the Everolimus- versus the Paclitaxel-Eluting Stents in a Consecutive Cohort of Patients at a Tertiary Medical Center
Q46265631Outcomes of overlapping heterogeneous drug-eluting stents versus homogeneous drug-eluting stents for diffuse lesions in small coronary arteries
Q35354402Outcomes of small coronary artery stenting with bare-metal stents versus drug-eluting stents: results from the NHLBI Dynamic Registry
Q37077532Outcomes of stenting with overlapping drug-eluting stents versus overlapping drug-eluting and bare-metal stents for the treatment of diffuse coronary lesions
Q36614116Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent
Q44130145Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis
Q50962970Paclitaxel-eluting composite fibers: drug release and tensile mechanical properties.
Q27691306Paclitaxel: new uses for an old drug
Q37878377Pathogenesis of implant-associated infection: the role of the host
Q39505785Pathologic Etiologies of Late and Very Late Stent Thrombosis following First-Generation Drug-Eluting Stent Placement
Q41808121Pathological perspective of drug-eluting stent thrombosis
Q64938119Pathology of Endovascular Stents.
Q36934746Pathology of atherosclerosis and stenting
Q36126274Pathology of drug-eluting versus bare-metal stents in saphenous vein bypass graft lesions
Q34268046Patient preferences for coronary artery bypass graft surgery or percutaneous intervention in multivessel coronary artery disease
Q40947858Percutaneous coronary intervention and drug-eluting stents
Q36752079Percutaneous coronary intervention for left main coronary artery disease
Q37786640Percutaneous coronary intervention for small-vessel coronary disease: highlight on the everolimus-eluting stent
Q35813673Percutaneous coronary intervention in diabetics
Q34126291Percutaneous coronary intervention of moderate to severe calcified coronary lesions: insights from the National Heart, Lung, and Blood Institute Dynamic Registry
Q30479477Percutaneous coronary intervention: recommendations for good practice and training
Q36216817Percutaneous coronary revascularization in diabetics: from balloon angioplasty to drug-eluting stents
Q46600768Percutaneous therapy of bifurcation lesions with drug-eluting stent implantation: the Culotte technique revisited
Q51036735Percutaneous treatment of coronary bifurcations: lesion preparation before provisional bare metal stenting and subsequent immunosuppression with oral prednisone. The IMPRESS-Y study.
Q51531976Performance of everolimus-eluting versus paclitaxel-eluting coronary stents in small vessels: results from the SPIRIT III and SPIRIT IV clinical trials.
Q38084549Perioperative management of antiplatelet therapy in patients with drug-eluting stents.
Q51168063Perivascular paclitaxel wraps block arteriovenous graft stenosis in a pig model.
Q37756979Pharmacological prevention and management of restenosis
Q30782165Physical characterization of alginate-Pluronic F127 gel for endoluminal NABDs delivery.
Q40099411Planned versus provisional rotational atherectomy for severe calcified coronary lesions: Insights From the ROTATE multi-center registry
Q51373459Plaque sealing--a concept waiting for support.
Q45924939Poly(ester amide) co-polymers promote blood and tissue compatibility.
Q45900667Poly-(L-lactic acid) and citric acid-crosslinked gelatin composite matrices as a drug-eluting stent coating material with endothelialization, antithrombogenic, and drug release properties.
Q36933167Polyelectrolyte multilayers promote stent-mediated delivery of DNA to vascular tissue
Q51009195Polymer-free versus permanent polymer drug eluting stents in coronary artery disease: A meta-analysis of 10 RCTs with 6575 patients.
Q59110902Polymers for Cardiovascular Stent Coatings
Q41486571Predictors of diffuse-type in-stent restenosis following drug-eluting stent implantation
Q44570978Predictors of early and late target lesion revascularization after drug-eluting stent implantation
Q44343388Prevalence and predictors of premature discontinuation of dual antiplatelet therapy after drug-eluting stent implantation: importance of social factors in Asian patients
Q64105906Prevalence of Decreased Myocardial Blood Flow in Symptomatic Patients with Patent Coronary Stents: Insights from Low-Dose Dynamic CT Myocardial Perfusion Imaging
Q35938663Preventing restenosis in early drug-eluting stent era: recent developments and future perspectives
Q51192882Proceedings of the TCT: questions surround antithrombotic therapy in coronary DES implantation.
Q35954252Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation
Q53570426Prognostic significance of asymptomatic coronary artery disease in patients with diabetes and need for early revascularization therapy.
Q40459284Progression of noncalcified and calcified coronary plaque by CT angiography in SLE.
Q92093210Prospective multicentre open-label randomised controlled trial of 3-month versus 12-month dual antiplatelet therapy after implantation of the new generation biodegradable polymer sirolimus TARGET-eluting coronary stent: protocol of the TARGET DAPT t
Q35763063Prostate cancer and coronary heart disease: correlation or coincidence?
Q38166727QCA, IVUS and OCT in interventional cardiology in 2011.
Q45398663Racial differences in long-term outcomes after percutaneous coronary intervention with paclitaxel-eluting coronary stents
Q37978664Radiation therapy for dialysis access stenosis: unfulfilled promise or false expectations
Q46005297Randomized comparison of the Nobori biolimus A9-eluting stent with the sirolimus-eluting stent in patients with stenosis in native coronary arteries.
Q46886141Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels
Q38379261Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial
Q28482627Rapamycin regulates the expression and activity of Krüppel-like transcription factor 2 in human umbilical vein endothelial cells
Q28213719Rapid desensitization protocols for patients with cardiovascular disease and aspirin hypersensitivity in an era of dual antiplatelet therapy
Q31119076Rationale and study design of the CardioGene Study: genomics of in-stent restenosis.
Q37711403Real World Application of Stenting of Unprotected Left Main Coronary Stenosis: A Single-Center Experience
Q34548825Real-world safety and effectiveness outcomes of a zotarolimus-eluting stent: final 3-year report of the RESOLUTE International study
Q36273744Recent advances in endoluminal revascularization for intracranial atherosclerotic disease
Q46651488Recurrence of in-stent restenosis in cardiac allograft vasculopathy following implantation of a sirolimus-eluting stent
Q28537759Red blood cell distribution width and long-term outcome in patients undergoing percutaneous coronary intervention in the drug-eluting stenting era: a two-year cohort study
Q39928221Reduction in incomplete stent apposition area caused by jailed struts after single stenting at left main bifurcation lesions: micro-CT analysis using a three-dimensional elastic bifurcated coronary artery model
Q36354513Reduction of intimal hyperplasia in injured rat arteries promoted by catheter balloons coated with polyelectrolyte multilayers that contain plasmid DNA encoding PKCδ.
Q36848895Release of plasmid DNA from intravascular stents coated with ultrathin multilayered polyelectrolyte films
Q46656412Resistance to platelet antiaggregants: an important cause of very late thrombosis of drug eluting stents? Observations from five cases
Q40752196Resistant in-stent restenosis in the drug eluting stent era.
Q38201505Resolute zotarolimus-eluting coronary stent system for the treatment of coronary artery disease
Q36486769Restenosis related to percutaneous coronary intervention has been solved?
Q33791885Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis
Q38201161Revascularization strategies for patients with stable coronary artery disease.
Q36759494Review of the TAXUS Liberté SR paclitaxel-eluting coronary stent
Q58584593Rhombic-Shaped Channel Stent with Enhanced Drug Capacity and Fatigue Life
Q37260877Role of E2F1-cyclin E1-cyclin E2 circuit in human coronary smooth muscle cell proliferation and therapeutic potential of its downregulation by siRNAs.
Q36433005Role of cAMP-phosphodiesterase 1C signaling in regulating growth factor receptor stability, vascular smooth muscle cell growth, migration, and neointimal hyperplasia
Q35584915Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial).
Q92189384Rotational Atherectomy: A Contemporary Appraisal
Q33734969Routine Angiographic Follow-Up versus Clinical Follow-Up after Percutaneous Coronary Intervention in Acute Myocardial Infarction
Q28539865Safety and efficacy of biodegradable drug-eluting vs. bare metal stents: a meta-analysis from randomized trials
Q46529943Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials
Q51189269Safety and efficacy with drug-eluting stent in ST-segment elevation and non-ST-segment elevation myocardial infarction.
Q47783141Safety and feasibility of drug-eluting stent implantation at vertebral artery origin: the first case series in Asians
Q57730945Safety of drug-coated stents
Q37139276Safety of drug-eluting stents
Q51310341Same or Different Drug-Eluting Stent Re-Implantation for Drug-Eluting Stent Restenosis: An Assessment Including Second-Generation Drug-Eluting Stents.
Q43198903Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial
Q43809511Selective drug-eluting stent implantation for high-risk patients with acute ST-elevation myocardial infarction: rationale and safety.
Q82477429Serial angiographic and intravascular ultrasound evaluation to interrogate the presence of late "catch-up" phenomenon after Cypher® sirolimus-eluting stent implantation
Q46134862Short and long-term benefits of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials
Q50450276Short- and long-term benefits of drug-eluting stents compared to bare metal stents even in treatment for large coronary arteries.
Q37687216Short- and long-term outcomes of percutaneous coronary intervention in patients with low, intermediate and high ejection fraction
Q36897187Short- and long-term outcomes of single bare metal stent versus drug eluting stent in nondiabetic patients with a simple de novo lesion in the middle and large vessel
Q47433386Short-term follow-up results of drug-eluting stenting in premature coronary artery disease patients with multiple atherosclerotic risk factors
Q36335179Should degenerated saphenous vein grafts routinely be sealed with drug-eluting stents?
Q37086357Simultaneous "hybrid" percutaneous coronary intervention and minimally invasive surgical bypass grafting: feasibility, safety, and clinical outcomes
Q64898132Simultaneous stent obstruction of triple vessels with very late stent thrombosis after implantation of sirolimus-eluting stents.
Q38970275Single or dual antiplatelet therapy after PCI.
Q50941839Single-center randomized evaluation of paclitaxel-eluting versus conventional stent in acute myocardial infarction (SELECTION).
Q41390902Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries.
Q36376420Sirolimus- or paclitaxel-eluting stents for coronary artery revascularisation
Q35925484Sirolimus- or paclitaxel-eluting stents to prevent coronary artery restenosis
Q35784102Sirolimus- versus paclitaxel-eluting stents in patients with stenosis in a native coronary artery
Q35707420Sirolimus-eluting dextran and polyglutamic acid hybrid coatings on AZ31 for stent applications.
Q57916573Solely abluminal drug release from coronary stents could possibly improve reendothelialization
Q82511623Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention
Q38126880Stent evaluation with optical coherence tomography.
Q45930222Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period.
Q90379953Stent thrombosis distal to the segment showing early in-stent restenosis with everolimus-eluting stent
Q38014979Stent thrombosis in patients with chronic kidney disease
Q40243361Stent thrombosis in real-world patients: a comparison of drug-eluting with bare metal stents
Q52581576Stent thrombosis rates the first year and beyond with new- and old-generation drug-eluting stents compared to bare metal stents.
Q37996688Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
Q40889474Stent underexpansion in angiographic guided percutaneous coronary intervention, despite adjunctive balloon post-dilatation, in drug eluting stent era.
Q46496368Stent-based delivery of ABT-578 via a phosphorylcholine surface coating reduces neointimal formation in the porcine coronary model
Q38729698Stent-induced tracheal stenosis can be predicted by IL-8 expression in rabbits.
Q36360162Stents or surgery: the case for stents
Q38979758Stents: Biomechanics, Biomaterials, and Insights from Computational Modeling.
Q85455953Study of novel coating strategy for coronary stents: simutaneous coating of VEGF and anti- CD34 antibody
Q51007148Success, safety, and efficacy of implantation of diamond-like carbon-coated stents.
Q38262668Surgical versus percutaneous revascularization in patients with multivessel coronary artery disease
Q34465141Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis
Q35796636Systematic Review of Chinese Herbal Medicines for Preventing in-Stent Coronary Restenosis after Percutaneous Coronary Intervention
Q51385693Systemic inflammation after drug-eluting stent placement.
Q51022640Systemic nanoparticle paclitaxel (nab-paclitaxel) for in-stent restenosis I (SNAPIST-I): a first-in-human safety and dose-finding study.
Q42085307Target lesion revascularisation in patients treated with a sirolimus-eluting or paclitaxel-eluting stent
Q59813525Targeted Delivery of Bioactive Molecules for Vascular Intervention and Tissue Engineering
Q28543965Targeted inhibitory effect of Lenti-SM22alpha-p27-EGFP recombinant lentiviral vectors on proliferation of vascular smooth muscle cells without compromising re-endothelialization in a rat carotid artery balloon injury model
Q42829200Targeting drug-eluting stents to lesions at high risk of restenosis: a flawed approach?
Q36321778Technology Insight: an overview of research in drug-eluting stents
Q37387217Temporal Trends in Clinical Outcomes Following Percutaneous Coronary Intervention in Patients with Renal Insufficiency
Q35526303Temporal trends in percutaneous coronary intervention outcomes among older patients in the United States
Q36559145The 5-year projection on the future of interventional cardiology
Q39465229The Absorb bioresorbable vascular scaffold for the treatment of coronary artery disease
Q35998044The FDA Review Process for Cardiac Medical Devices in Children: A Review for the Clinician
Q36117819The Food and Drug Administration and pragmatic clinical trials of marketed medical products
Q50993393The Sirolimus-eluting coronary stent in daily routine practice in Germany: trends in indications over the years. Results from the prospective multi-centre German Cypher Stent Registry.
Q34996907The association of diabetes mellitus with clinical outcomes after coronary stenting: a meta-analysis
Q36405134The cell cycle: a critical therapeutic target to prevent vascular proliferative disease
Q39840291The comparative safety of bare-metal and drug-eluting intracoronary stents
Q36735675The costs and quality-of-life outcomes of drug-eluting coronary stents: a systematic review
Q36066019The drug-based pipeline against restenosis
Q35987013The drug-eluting stent information gap.
Q45004975The e-Cypher registry: objectives and organization
Q80275766The early invasive strategy revisited: FRISC II at 5 years
Q37121773The economic burden of complications during percutaneous coronary intervention
Q46527906The effects of vinblastine on endothelial cells
Q34175429The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease
Q38012002The importance of the endothelium in atherothrombosis and coronary stenting
Q40534392The influence of advancing age on implantation of drug-eluting stents.
Q50921953The lack of endothelization after drug-eluting stent implantation as a cause of fatal late stent thrombosis.
Q50934202The paclitaxel-eluting Coroflex Please stent pilot study (PECOPS I) : the one-year clinical follow-up.
Q37387972The paclitaxel-eluting PTCA-balloon in combination with a cobalt-chromium stent in two different sequences to treat de novo coronary artery lesions: an angiographic follow up study
Q39755962The potential of surgical strategy for incomplete stent apposition after implantation of a sirolimus eluting stent
Q36225762The power prior: theory and applications
Q43294410The risk of definitive stent thrombosis is increased after "off-label" stent implantation irrespective of drug-eluting stent or bare-metal stent use.
Q37248010The risks and benefits of drug-eluting stents in the setting of STEMI.
Q36982530The role of CABG in the era of drug-eluting stents: a surgeon's viewpoint
Q34720419The role of mitosis in LDL transport through cultured endothelial cell monolayers
Q28200757The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease
Q37362714The safety of drug-eluting stents
Q36405138The vascular effects of cilostazol
Q38199360Therapy in ST-elevation myocardial infarction: reperfusion strategies, pharmacology and stent selection.
Q36748161Therapy insight: diabetes and drug-eluting stents
Q48212416Third generation dual-source CT enables accurate diagnosis of coronary restenosis in all size stents with low radiation dose and preserved image quality.
Q43842750Third in-stent restenosis in sirolimus eluting stents: predictors of the next restenosis
Q40097851Thrombosis after stent implantation: how much of a problem is there?
Q39787837Thrombosis: the last frontier of coronary stenting?
Q38265789Titania nanotube arrays for local drug delivery: recent advances and perspectives
Q54069775Titanium-nitride-oxIde-coated stents multicenter registry in diaBEtic patienTs: the TIBET registry.
Q46537651Titanium-nitride-oxide-coated Titan-2 bioactive coronary stent: a new horizon for coronary intervention
Q48288451Total sleep deprivation augments balloon angioplasty-induced neointimal hyperplasia in rats
Q35485519Translational research: current status, challenges and future strategies.
Q35771454Treatment of bifurcation lesions with two stents: one year angiographic and clinical follow up of crush versus T stenting
Q43281173Treatment of stenoses of vertebral artery origin using short drug-eluting coronary stents: improved follow-up results
Q47201507Treatment of symptomatic middle cerebral artery stenosis with balloon-mounted stents: long-term follow-up at a single center
Q36239509Treatment of unprotected left main coronary artery disease with drug-eluting stents: is it time for a randomized trial?
Q36335174Treatment of unprotected left main coronary artery stenosis in the drug-eluting stent era.
Q51110906Trend to move from permanent metals to degradable, multifunctional polymer or metallic implants in the example of coronary stents.
Q92153486Two Years Efficacy of Paclitaxel-Coated Balloon Dilation for In-Stent Renal Artery Restenosis Due to Takayasu Arteritis
Q39459597Two-Year Follow-up of Sirolimus-Eluting Stents versus Paclitaxel-Eluting Stents in Acute Myocardial Infarction
Q41018522Two-year clinical outcomes of the NOBORI biolimus-eluting stents versus XIENCE/PROMUS everolimus-eluting stents in small vessel disease
Q45366439Two-year clinical outcomes with paclitaxel-eluting coronary stents in patients with chronic total occlusions: analysis from the TAXUS ARRIVE program
Q51487998Two-year follow-up intravascular ultrasound analysis after bare metal stent implantation in 120 lesions.
Q28073031Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment
Q47133703Undesired Outcomes of the Catania Stent Compared to the Xience Stent in Patients Undergoing Angioplasty: A Double-Blind Randomized Controlled Trial
Q44986882Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial
Q36266053Update on drug-eluting coronary stents
Q36375853Update on drug-eluting stents for prevention of restenosis
Q47413643Update on multidetector coronary CT angiography of coronary stents: in vitro evaluation of 29 different stent types with dual-source CT.
Q38544557Update on percutaneous intervention for left main coronary artery stenosis
Q36985317Update on stents: recent studies on the TAXUS stent system in small vessels.
Q38864003Usage patterns and 1-year outcomes with the TAXUS Liberté stent: results of the TAXUS OLYMPIA registry
Q51252575Use of an audible ultrasonic flowmeter to locate deeply buried coronary arteries for off-pump coronary artery bypass grafting.
Q50930121Usefulness of drug eluting stent in percutaneous coronary intervention--a single center experience in Taiwan.
Q53971688Utility of drug-eluting stents in complex lesions and high-risk patients.
Q83163572Utility of myocardial fractional flow reserve for prediction of restenosis following sirolimus-eluting stent implantation
Q39335623Variability in utilization of drug eluting stents in United States: Insights from nationwide inpatient sample.
Q38099516Vascular access in haemodialysis: strengthening the Achilles' heel
Q84109345Vascular disease: Endovascular treatment of vertebral artery stenosis
Q42339589Vascular pathology as a result of drug-eluting stents
Q33598021Vascular response profiles following a nano polymer-free sirolimus-eluting stent implantation assessed by optical coherence tomography in a porcine model
Q35925488Vascular restenosis - striving for therapy
Q37843083Vascular smooth muscle cell proliferation in restenosis
Q44288213Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model
Q46669724Very late stent thrombosis after dual antiplatelet therapy discontinuation in a patient with a history of acute stent thrombosis
Q30251867Very late stent thrombosis with second generation drug eluting stents compared to bare metal stents: Network meta-analysis of randomized primary percutaneous coronary intervention trials
Q86257244Very long-term follow-up of strut apposition and tissue coverage with Biolimus A9 stents analyzed by optical coherence tomography
Q42242546Vessel Size and Long-Term Outcomes After Limus-Based Drug-Eluting Stent Implantation Focusing on Medium- and Small-Diameter Vessels
Q36335468Vinpocetine suppresses pathological vascular remodeling by inhibiting vascular smooth muscle cell proliferation and migration
Q48277634Visit-to-visit variability of systolic blood pressure predicts all-cause mortality in patients received percutaneous coronary intervention with drug-eluting stents
Q84982959What Is the Effectiveness of Drug-Eluting Stents in the Treatment of ST-Elevation Myocardial Infarction? - Should Drug-Eluting Stents Be Indicated for Patients With Acute Coronary Syndrome? (Pro) -
Q30958774When are drug-eluting stents effective? A critical analysis of the presently available data
Q53670933When is evidence sufficient for decision-making? A framework for understanding the pace of evidence adoption.
Q35989916Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part II.
Q43127112Wnt4/β-catenin signaling pathway modulates balloon-injured carotid artery restenosis via disheveled-1.
Q37472070Xience V everolimus-eluting coronary stent
Q24202652Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease
Q24203974Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease
Q41559941Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial
Q58227221Zotarolimus-eluting stent utilization in small-vessel coronary artery disease (ZEUS)
Q46496790Zotarolimus-eluting vs. sirolimus-eluting coronary stents in patients with and without acute coronary syndromes: a SORT OUT III substudy
Q83209300[Acute coronary syndrome - a challenge for the cooperation between outpatient and inpatient care]
Q85867313[Antithrombocytic therapy and PCI. Duration of therapy after DCB/stents/scaffolds]
Q81565632[Failure in the implantation of drug eluting stents. Frequency and related factors]
Q50933577[Implants for drug substance delivery].
Q83901875[New developments in drug-eluting stents]
Q83189210[Revascularization of coronary artery disease in diabetes mellitus]
Q54585506[Stent therapy with diabetic patients who have coronary artery disease].
Q34504964microRNAs Distinctively Regulate Vascular Smooth Muscle and Endothelial Cells: Functional Implications in Angiogenesis, Atherosclerosis, and In-Stent Restenosis
Q53536509p55γ functional mimetic peptide N24 blocks vascular proliferative disorders.

Search more.